Journal of Life Science (생명과학회지)

Korean Society of Life Science (한국생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Structure Determination of Macrolactin Compounds with Antibacterial Activities Isolated from Bacillus polyfermenticus KJS-2

Bacillus polyfermenticus KJS-2에서 분리된 항생물질 마크로락틴류의 구조결정

  • Kim, Dong-Hee (Research and Development Center, Daewoo Pharmaceutical Co,. Ltd.) ;
  • Kang, Kyung-Ran (Research and Development Center, Daewoo Pharmaceutical Co,. Ltd.) ;
  • Kim, Hyun-Woo (Technical Research Institute, Daesun Distilling Co., Ltd.) ;
  • Yoon, Si-Yeol (Department of Pharmaceutical Engineering, Inje University) ;
  • Kim, Chun-Gyu (Department of Pharmaceutical Engineering, Inje University) ;
  • Yamaguchi, Tokutaro (Department of Pharmaceutical Engineering, Sun Moon University) ;
  • Sohng, Jae-Kyung (Department of Pharmaceutical Engineering, Sun Moon University) ;
  • Kang, Jae-Seon (Department of Pharmacy, Kyungsung University)
  • Received : 2010.11.05
  • Accepted : 2010.12.16
  • Published : 2010.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

In this study, we isolated five macrolactin compounds from a fermentation broth of Bacillus polyfermenticus KJS-2. The macrolactin compounds were structurally identified as macrolactin A (MA), 7-O-malonyl macrolactin A (MMA), 7-O-succinyl macrolactin A (SMA), macrolactin E (ME) and macrolactin F (MF) via a variety of NMR techniques, COZY, DEPT, HMQC and HMBC, and mass and specific rotation assays. The three macrolactin compounds, MA, MMA and SMA, profoundly inhibited the growth of both vancomycin-resistant Enterococci (VREs) and methicillin-resistant Staphylococcus aureus (MRSA), the inhibition of which were estimated via a disc agar diffusion bioassay. MA, MMA, and SMA exhibited antibacterial activities superior to those of vancomycin and teicoplanin.

바실러스 폴리퍼멘티쿠스 케이제이에스-2의 발효액에서 5 종류의 마크로락틴을 분리하였다. 각각의 구조를 분석한 결과로 마크로락틴 에이, 말로닐 마크로락틴 에이, 숙시닐 마크로락틴 에이, 마크로락틴 이, 마크로락틴 에프 등으로 규명되었다. 특히 3종의 항생제인 마크로락틴 에이, 말로닐 마크로락틴 에이, 숙시닐 마크로락틴 에이는 반코마이신 내성 장구균과 메치실린 내성 황생포도상구균에 효과적으로 성장억제를 나타내었다. 이것은 반코마이신이나 테이코플라닌보다 우수한 항생효과를 보였다.

Keywords

References

  1. Arthur, M. and R. Quintiliani. 2001. Regulation of VanA‑and VanB‑type glycopeptide resistance in enterococci. Antimicrob. Agents Chemother. 45, 375-381. https://doi.org/10.1128/AAC.45.2.375-381.2001
  2. Auckland, C., L. Teare, F. Cooke, M. E. Kaufmann, M. Warner, G. Jones, K. Bamford, H. Ayles, and A. P. Johnson. 2002. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J. Antimicrob. Chemother. 50, 743-746. https://doi.org/10.1093/jac/dkf246
  3. Bagga, B. and J. L. Shenep. 2010. Management of infections caused by vancomycin-resistant Gram-positive bacteria. Pediatr. Infect. Dis. J. 29, 662-664. https://doi.org/10.1097/INF.0b013e3181e78efc
  4. Choi, S. W., D. H. Bai, J. H. Yu, and C. S. Shin. 2003. Characteristics of the squalene synthase inhibitors produced by a Streptomyces species isolated from soils. Can. J. Microbiol. 49, 663-668. https://doi.org/10.1139/w03-084
  5. Cosgrove, S. E., G. Sakoulas, E. N. Perencevich, M. J. Schwaber, A. W. Karchmer, and Y. Carmeli. 2003. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin. Infect. Dis. 36, 53-59. https://doi.org/10.1086/345476
  6. Fraser, T. G., C. Hansen, and J. K. Long. 2006. Newer antibiotics for serious gram-positive infections. Cle. Clin. J. Med. 73, 847-853. https://doi.org/10.3949/ccjm.73.9.847
  7. Goll, C., P. Balmer, F. Schwab, H. Rüden, and T. Eckmanns. 2007. Different trends of MRSA and VRE in a German Hospital, 1999-2005. Infection 35, 245-249. https://doi.org/10.1007/s15010-007-6234-5
  8. Gustafson, K., M. Roman, and W. Fenical. 1989. The macrolactins, a novel class of antiviral and cytotoxic macrolides from a deep-sea marine bacterium. J. Am. Chem. Soc. 111, 7519-7524. https://doi.org/10.1021/ja00201a036
  9. Han, J. S., J. H. Cheng, T. M. Yoon, J. Song, A. Rajkarnikar, W. G. Kim, I. D. Yoo, and Y. Y. Yang. 2005. Biological control agent of common scab disease by antagonistic strain Bacillus sp. sunhua. J. Appl. Microbiol. 99, 213-221. https://doi.org/10.1111/j.1365-2672.2005.02614.x
  10. Jaruchoktaweechai, C., K. Suwanborirux, S. Tanasupawatt, P. Kittakoop, and P. Menasveta. 2000. New macrolactins from a marine Bacillus sp. Sc026. J. Nat. Prod. 63, 984-986. https://doi.org/10.1021/np990605c
  11. Kim, H. H., W. G. Kim, I. J. Ryoo, C. J. Kim, J. E. Suk, K. H. Han, S. Y. Hwang, and I. D. Yoo. 1997. Neuronal cell protection activity of macrolactin A produced by Actinomadura sp. J. Microbiol. Biotechnol. 7, 429-434.
  12. Kim, K. M., M. J. Kim, D. H. Kim, Y. S. Park, and J. S. Kang. 2009. Characterization of Bacillus polyfermenticus KJS-2 as a Probiotic. J. Microbiol. Biotechnol. 19, 1013-1018. https://doi.org/10.4014/jmb.0903.113
  13. Lee, K. H., K. D. Jun, W. S. Kim, and H. D. Paik. 2001. Partial characterization of polyfermenticin SCD, a newly identified bacteriocin of Bacillus polyfermenticus. Lett. Appl. Microbiol. 32, 146-151. https://doi.org/10.1046/j.1472-765x.2001.00876.x
  14. Lee, S. J., J. Y. Cho, J. H. Moon, K. D. Park, Y. J. Lee, and K. H. Park. 2004. Isolation and characterization of antimicrobial substance macrolactin A produced from Bacillus amyloliquefaciens CHO104 isolated from soil. J. Microbiol. Biotechnol. 14, 525-531.
  15. Lentino, J. R., M. Narita, and V. L. Yu. 2008. New antimicrobial agents as therapy for resistant gram-positive cocci. Eur. J. Clin. Microbiol. Infect. Dis. 27, 3-15. https://doi.org/10.1007/s10096-007-0389-y
  16. Nagao, T., M. Adachi, M. Sakai, M. Nishijima, and H. Sano. 2001. Novel macrolactins as antibiotic lactones from a marine bacterium. J. Antibiot. 54, 333-339. https://doi.org/10.7164/antibiotics.54.333
  17. Neu, H. C. 1992. The crisis in antibiotic resistance. Science 254, 1064-1073.
  18. Norrby, S. R. 1995. Emerging antibiotic resistance in Gram positive bacteria: return to the pre-antibiotic era? HKMJ. 1, 129-135.
  19. Presterl, E., W. Graninger, and A. Georgopoulos. 1993. The efficacy of teicoplanin in the treatment of endocarditis caused by Gram-positive bacteria. J. Antimicrob. Chemother. 31, 755-766. https://doi.org/10.1093/jac/31.5.755
  20. Rice, L. B. 2006. Antimicrobial resistance in gram-positive bacteria. Am. J. Infect. Control. 34, S11-S19. https://doi.org/10.1016/j.ajic.2006.05.220
  21. Romero-Tabarez, M., R. Jansen, M. Sylla, H. Lunsdorf, S. Haubler, D. A. Santosa, K. N. Timmis, and G. Molinari. 2006. 7-O-malonyl macrolactin A, a new macrolactin antibiotic from Bacillus subtilis active against methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococci, and a small-colony variant of Burkholderia cepacia. Antimicrob. Agents Chemother. 50, 1701-1709. https://doi.org/10.1128/AAC.50.5.1701-1709.2006
  22. Sohn, M. J., C. J. Zheng, and W. G. Kim. 2008. Macrolactin S, a new antibacterial agent with Fab G-inhibitory activity from Bacillus sp. AT28. J. Antibiot. 61, 687-691. https://doi.org/10.1038/ja.2008.98
  23. Tsiodras, S., H. S. Gold, G. Sakoulas, G. M. Eliopoulos, C. Wennersten, L. Venkataraman, and R. C. Moellering. 2001. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358, 207-208. https://doi.org/10.1016/S0140-6736(01)05410-1
  24. Van der Auwera, P., M. Aoun, and F. Meunier. 1991. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts. Antimicrob. Agents Chemother. 35, 451-457. https://doi.org/10.1128/AAC.35.3.451
  25. Von Baum, H., J. F. Ober, C. Wendt, R. P. Wenzel, and M. B. Edmond. 2005. Antibiotic-resistant bloodstream infections in hospitalized patients: specific risk factors in a high-risk population? Infection. 33, 320-326. https://doi.org/10.1007/s15010-005-5066-4
  26. Xue, C., L. Tian, M. Xu, Z. Deng, and W. Lin. 2008. A new 24-membered lactone and a new polyene $\delta$-lactone from the marine bacterium Bacillus Marinus. J. Antibiot. 61, 668-674. https://doi.org/10.1038/ja.2008.94
  27. Yoo, J. S., C. J. Zheng, S. K. Lee, J. H. Kwak, and W. G. Kim. 2006. Macrolactin N, a new peptide deformylase inhibitor produced by Bacillus subtilis. Bioorg. Med. Chem. Lett. 16, 4889-4892. https://doi.org/10.1016/j.bmcl.2006.06.058
  28. Zheng, C. J., S. K. Lee, C. H. Lee, and W. G. Kim. 2007. Macrolactins O-R, glycosylated 24-membered lactones from Bacillus sp. AH159-1. J. Nat. Prod. 70, 1632-1635. https://doi.org/10.1021/np0701327
  29. Zurenko, G. E., B. H. Yagi, R. D. Schaadt, J. W. Allison, J. O. Kilburn, S. E. Glickman, D. K. Hutchinson, M. R. Barbachyn, and S. J. Brickner. 1996. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother. 40, 839-845.

Cited by

  1. Isolation and Characterization of Bacillus subtilis MP56 with Antimicrobial Activity against MDR (Multi Drug Resistant) Strains vol.49, pp.1, 2013, https://doi.org/10.7845/kjm.2013.017
  2. The Effect of Nakai Extract and KJS-2 on Atopic Dermatitis induced by DNCB in mice vol.38, pp.3, 2017, https://doi.org/10.13048/jkm.17023